Abstract
Many difficult-to-treat clinical entities in the cardiovascular field are characterized by pronounced sympathetic overactivity, including resistant hypertension and heart failure, underlining the need to explore therapeutic options beyond pharmacotherapy. Autonomic modulation via carotid baroreceptor activation has already been evaluated in clinical trials for resistant hypertension, and relevant outcomes with regard to safety and efficacy of the technique are critically presented. The pathophysiological background of heart failure renders carotid baroreceptor stimulation a potential treatment candidate for the disease. Available data from animal models with heart failure point towards significant cardioprotective benefits of this innovative technique. Accordingly, the effects of baroreceptor activation treatment (BAT) on cardiac parameters of hypertensive patients are well-promising, setting the basis for upcoming clinical trials with baroreflex activation on patients with heart failure. However, as the potential therapeutic of BAT unfolds and new perspectives are highlighted, several concerns are raised that should be meticulously addressed before the wide application of this invasive procedure is set in the limelight.
Keywords: Carotid baroreceptor stimulation, baroreflex, hypertension, heart failure, resistant hypertension, heart failure with preserved ejection fraction, sympathetic nervous system.
Current Vascular Pharmacology
Title:Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure
Volume: 12 Issue: 1
Author(s): Doumas M., Faselis C., Kokkinos P., Anyfanti P., Tsioufis C. and Papademetriou V.
Affiliation:
Keywords: Carotid baroreceptor stimulation, baroreflex, hypertension, heart failure, resistant hypertension, heart failure with preserved ejection fraction, sympathetic nervous system.
Abstract: Many difficult-to-treat clinical entities in the cardiovascular field are characterized by pronounced sympathetic overactivity, including resistant hypertension and heart failure, underlining the need to explore therapeutic options beyond pharmacotherapy. Autonomic modulation via carotid baroreceptor activation has already been evaluated in clinical trials for resistant hypertension, and relevant outcomes with regard to safety and efficacy of the technique are critically presented. The pathophysiological background of heart failure renders carotid baroreceptor stimulation a potential treatment candidate for the disease. Available data from animal models with heart failure point towards significant cardioprotective benefits of this innovative technique. Accordingly, the effects of baroreceptor activation treatment (BAT) on cardiac parameters of hypertensive patients are well-promising, setting the basis for upcoming clinical trials with baroreflex activation on patients with heart failure. However, as the potential therapeutic of BAT unfolds and new perspectives are highlighted, several concerns are raised that should be meticulously addressed before the wide application of this invasive procedure is set in the limelight.
Export Options
About this article
Cite this article as:
M. Doumas, C. Faselis, P. Kokkinos, P. Anyfanti, C. Tsioufis and V. Papademetriou, Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990138
DOI https://dx.doi.org/10.2174/15701611113119990138 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets Vascular Dysfunction in the Brain; Implications for Heavy Metal Exposures
Current Hypertension Reviews The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture
Current Neurovascular Research Therapeutic Potential of Heme Oxygenase-1/carbon Monoxide System Against Ischemia-Reperfusion Injury
Current Pharmaceutical Design Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition Comparison between Two Calcium Antagonists: Blood Pressure Reduction and Renal Effects in Hypertensive Patients with Type 2 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Validation of Two High-Performance Liquid Chromatographic Methods for the Analysis of Nadolol and Propranolol Hydrochloride Following In Vitro Transdermal Diffusion Studies
Current Pharmaceutical Analysis Editorial: [Hot Topic: Nanotechnology and Patents in Agriculture, Food Technology, Nutrition and Medicine - Advantages and Risks]
Recent Patents on Food, Nutrition & Agriculture Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Targeting the Endothelial Ca2+ Toolkit to Rescue Endothelial Dysfunction in Obesity Associated-Hypertension
Current Medicinal Chemistry Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation
Mini-Reviews in Medicinal Chemistry Screening for Inhibitors of Microglia to Reduce Neuroinflammation
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome and Aging: Calcium Signaling as Common Regulator
Current Diabetes Reviews Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design Editorial [Hot Topic: Complications in Pregnancy - Recent Developments in Preventive Strategies and Treatment Modalities (Executive Editor: A.C. Bolte)]
Current Pharmaceutical Design The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Current Vascular Pharmacology